Acquisition History Anacor was acquired by Pfizer in 2016 for approximately $5.2 billion. For BD, this signals Pfizer’s prior interest in boron-based small molecules and potential post-acquisition licensing, divestiture, or collaboration opportunities around Anacor’s boron chemistry platform or any remaining asset rights.

Strategic Fit With a boron chemistry platform and small-molecule focus, Anacor’s technology could complement companies seeking novel modalities in dermatology or infectious disease pipelines. Look for partnerships or licensing discussions with firms aiming to leverage boron chemistry for unique mechanism-of-action assets.

Financial Levers Current revenue range and substantial past funding suggest a moderate-to-high capital appetite for partnering programs, feasibility studies, or co-development deals that reduce upfront risk while enabling access to Anacor’s platform-derived candidates or know-how.

Market Positioning As a small organization with limited headcount, Anacor likely relies on external collaborators for development and scaling. This creates opportunities for clearly defined joint-venture structures, milestone-based deals, or CRO/CMO partnerships to advance assets without heavy internal resource commitments.

Competitive Signals The comparison with large pharma peers in similar sectors indicates potential interest from mid-to-large pharma or specialty biotechnology firms in acquiring or licensing niche platforms. Target firms with dermatology, infectious disease, or oncology portfolios seeking differentiated small-molecule assets.